Welcome to the 2nd hybrid symposium of MCI Forum!
We are pleased to invite you to participate in the second hybrid symposium of the “Mild Cognitive Impairment Forum”, 13:00 – 18:00, October 6, 2023, at:
”A new antibody drug has been approved in the United States, and is making headlines for shedding light on the treatment of mild dementia.
Last year we held the first MCI Symposium, which provided a general overview of the level of research in Japan. The 2nd MCI Symposium, co-hosted by Department of Neurology, Kyoto University School of Medicine (Professor Ryosuke Takahashi) and our institute, will be held on October 6 at the Inamori Hall, Shirankaikan, Kyoto University School of Medicine and ZOOM.
We invited Professor Weiner of UCSF, Executive Director of ADNI, the world’s largest and most advanced Alzheimer’s disease research group, to organize a symposium in a way that would mark the beginning of antibody medicine.
We hope that all interested parties/individuals will attend the symposium.”
Masanori Fukushima MD, PhD
Representative Director, Learning Health Society Institute
*****
「新しい抗体医薬が米国で承認され、軽度認知症の治療に光明が見出されたと大きな話題になっております。
私ども研究所は、昨年第一回MCI シンポジウムを開催し、わが国の研究水準を総覧しましたが、このたび京都大学医学部臨床神経学講座(高橋良輔教授)と弊研究所共催で第二回MCIシンポジウムを来たる10月6日、京都大学医学部芝蘭会館(ZOOM同時配信）にて開催します。
世界最大最先端のアルツハイマー病研究グループ米国ADNIの総帥であられるUCSF のWeiner 教授をお招きして、抗体医薬の幕開けにふさわしい形でシンポジウムをオーガナイズしました。
関心ある皆様にご参加いただければ幸甚です。」
LHS研究所 代表理事
福 島 雅 典
Program
■Opening Remarks: 13:00 – 13:10
Ryosuke Takahashi MD, PhD
Kyoto University
■Special Session: New era of Alzheimer’s Disease control
Chair: Ryosuke Takahashi MD, PhD
Takeshi Iwatsubo MD, PhD
13:10 – 13:35
Most recent advances in the Diagnosis and Treatment of Alzheimer’s Disease
Michael Weiner MD, PhD
University of California San Francisco (UCSF), USA
>>> Click here for summary
13:35 – 13:55 Discussion
13:55 – 14:20
Disease modification of Alzheimer’s disease in MCI and preclinical stages
Takeshi Iwatsubo MD, PhD
Tokyo University
>>> Click here for summary
14:20 – 14:25 Discussion
14:25 – 14:40
Discussion & Designated speech: Concerns about Lecanemab use in routine practice for MCI & early AD
Masanori Fukushima MD, PhD
Learning Health Society Institute
>>> Click here for summary
14:40 – 15:05
Pivotal trial of low-intensity pulsed ultrasound therapy for Alzheimer’s disease
Hiroaki Shimokawa MD, PhD
International University of Health and Welfare
>>> Click here for summary
15:05 – 15:10 Discussion
15:10 – 15:35 General Discussion
■Session I: Cohort study for early detection of AD
Chair: Akira Kuzuya MD, PhD
Kyoto University
15:35 – 15:50
Chinese Preclinical Alzheimer’s Disease Study (C-PAS): Design and Preliminary Findings
Lin Huang MD, PhD
Shanghai Jiaotong University
>>> Click here for summary
15:50 – 16:05
Current Status and Challenges of MCI Diagnosis in the Dementia Kobe Model
Hisatomo Kowa MD, PhD
Kobe University
>>> Click here for summary
16:05 – 16:20
Differential risk of Alzheimer’s disease in MCIs with elevated PET Abeta
Bin Zhou MD, PhD
Learning Health Society Institute
>>> Click here for summary
16:20 – 16:35 Panel Discussion
16:35 – 16:45 Break
■Session II: Frontiers in Alzheimer’s Disease
Chair: Ayae Kinoshita MD, PhD
Bin Zhou MD, PhD
16:45 – 17:00
Neurovascular approach for mild cognitive impairment
Masafumi Ihara MD, PhD
National Cerebral and Cardiovascular Center (NCVC)
>>> Click here for summary
17:00 – 17:15
Gut microbiota in dementia with Lewy bodies
Kinji Ohno MD, PhD
Nagoya University
>>> Click here for summary
17:15 – 17:30
Towards novel biomarkers and potential therapeutic targets for Alzheimer’s disease as a “synaptopathy”
Akira Kuzuya MD, PhD
Kyoto University
>>> Click here for summary
17:30 – 17:45 Panel Discussion
Closing Remarks: 17:45 – 18:00
Bin Zhou MD, PhD